UBS Group’s Translational Development Acquisition Corp TDAC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$24.2K Buy
+2,237
New +$24.2K ﹤0.01% 8324
2026
Q2
– Sell
-17,692
Closed -$187K – 11369
2026
Q1
$187K Buy
17,692
+5,009
+39% +$52.8K ﹤0.01% 6677
2025
Q4
$133K Sell
12,683
-21,367
-63% -$223K ﹤0.01% 6769
2025
Q3
$352K Buy
34,050
+34,031
+179,111% +$351K ﹤0.01% 6333
2025
Q2
$195 Hold
19
– – ﹤0.01% 9932
2025
Q1
$192 Buy
+19
New +$191 ﹤0.01% 9892

Other funds holding TDAC

UBS Group's TDAC Position: Q3 2026 in Review

UBS Group opened a new position in Translational Development Acquisition Corp (TDAC) in Q3 2026: 2,237 shares worth $24.2K. The stake represents ﹤0.01% of the portfolio and ranks #8324 among its holdings. This is a return to the name: UBS Group previously reported a position in TDAC as recently as Q1 2026.

UBS Group first reported a position in TDAC in Q1 2025 and has held it in 6 quarters since. The position peaked at $352K in Q3 2025. 37 funds tracked by Wall St. Rank hold TDAC as of Q3 2026.

  • UBS Group held 2,237 shares of Translational Development Acquisition Corp worth $24.2K as of Q3 2026.
  • Translational Development Acquisition Corp was a new UBS Group position in Q3 2026.
  • Translational Development Acquisition Corp made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #8324 holding.
  • UBS Group first reported a position in Translational Development Acquisition Corp in Q1 2025 and has held it in 6 quarters since.
  • UBS Group's Translational Development Acquisition Corp position peaked at $352K in Q3 2025.
  • 37 funds tracked by Wall St. Rank held Translational Development Acquisition Corp as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.